USFDA approves Sun Pharma's generic Flomax ANDA

NewsGuard 100/100 Score
Jul 16 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE:524715) announced that USFDA has granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Flomax ®, tamsulosin capsules.

These tamsulosin hydrochloride capsules, 0.4 mg are therapeutically equivalent to Flomax® Capsules 0.4 mg from Boehringer Ingelheim Pharmaceuticals, Inc.

Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

SOURCE Sun Pharmaceutical Industries Ltd.

www.sunpharma.com

Posted in: Men's Health News | Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Study highlights global fertility decline and its implications for the future
LabVantage celebrates customer success with record number of software deployments in FY 2024
Lancet Commission predicts sharp increase in global prostate cancer cases
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
SickKids study offers new path for pediatric rare disease clinical trials
Common HIV drugs linked to reduced Alzheimer's disease risk
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study highlights growing burden of neurological disorders worldwide